Natdac mechanism of action
Natdac active ingredient, Daclatasvir, exhibits dual modes of anti-viral activity. It binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly.
The drug is available in the form of tablets in various dosages of 60mg for oral administration only.
Natdac (daclatasvir), an NS5A replication complex inhibitor, is the first 12-week, all-oral therapy indicated for use with Sofosbuvir, for the treatment of hepatitis C (HCV) genotype 3 infections. The drug was manufactured by Natco Pharma Ltd. Natco Pharma Limited is an Indian pharmaceutical company based in Hyderabad, as a Private Limited Company to be in the business of Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances. Click here to view Natco Products…
Source : https://goo.gl/4DW2Pm
You must be logged in to post a comment.